Cardiac allograft arteriosclerosis is the most important limiting factor of long-term survival of heart transplant recipients. Several clinical studies have suggested the association between CMV infection and heart allograft arteriosclerosis, chronic rejection. To determine the temporal impact of CMV infection on the development of heart allograft arteriosclerosis we quantitated coronary angiograms obtained from 72 heart transplant recipients followed for 1-6 yr post-transplantation. To examine the graft function, echocardiography was evaluated. CMV infection was associated with early development of allograft arteriosclerosis manifested by intense diffuse pruning of the coronary arteries including their smallest branches already after the second post-transplant year. Even 6 yr post-transplantation the magnitude of arteriosclerotic changes was significantly higher in recipients with CMV infection compared with patients without infection (P < 0.02). No difference in echocardiographic parameters including ejection fraction (EF), left ventricular end diastolic diameter (LVEDD) and left ventricular mass (LVM) between recipients with and without CMV infection was recorded early after transplantation. However, when compared to recipients without CMV, the CMV accelerated chronic rejection seen in coronary angiography associated with impaired late graft function as judged by decreased EF in patients with CMV infection 6 yr post-transplantation (P < 0.02). No differences in LVEDD or LVM between the patient groups occurred. Taken together, these results suggest that CMV infection is associated with intense cardiac allograft arteriosclerosis affecting the whole coronary tree soon after transplantation. The intensity and magnitude of these chronic vascular wall changes increase and persist during subsequent years, indicating that the risk for graft loss and death due to chronic rejection is especially high during the first 5 post-transplant years in CMV-infected patients. Echocardiography may not be a sensitive method to distinguish patients with early CMV-accelerated allograft arteriosclerosis but coronary angiography must be performed.
Download full-text PDF |
Source |
---|
Catheter Cardiovasc Interv
January 2025
Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Background: Early detection of cardiac allograft vasculopathy after heart transplant (HTx) with invasive coronary angiography is challenging.
Aims: The study aimed to determine if computational techniques able to assess epicardial lesions, by means of Murray's law-based quantitative flow ratio (μFR), and microvascular physiology, by means of angiography microvascular resistance (AMR), enhance risk stratification in HTx patients with nonsignificant coronary artery disease.
Methods: The cohort consisted of 86 consecutive HTx patients (200 epicardial vessels) with stenosis < 50% at baseline.
Metabolites
October 2024
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Fibroblast activation protein (FAP) is a cell surface glycoprotein expressed by myofibroblasts in areas of active tissue remodeling. It plays a potentially important role in cardiac remodeling, atherosclerotic plaque formation, and plaque rupture. Given the distinct pathophysiology and morphology of different forms of atherosclerosis, we analyzed FAP expression in human coronary vessels with no coronary artery disease, atherosclerotic plaques at different levels of progression, and other distinct forms of coronary disease in post bypass vein grafting and cardiac allograft vasculopathy after a heart transplant.
View Article and Find Full Text PDFClin Exp Nephrol
November 2024
Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Background: We investigated the roles of renal volumetry and histological features in the assessment of preoperative and postoperative renal function in living kidney donors (LKDs) including high-risk marginal donors (MDs).
Methods: We included 128 LKDs who underwent donor nephrectomy at our institution between 2006 and 2022. Clinical and radiographic data were retrospectively obtained from medical charts.
Clin Transplant
November 2024
Department of Pharmacy, New York Presbyterian Hospital, New York City, New York, USA.
Background: Limited research has compared the relative risks and benefits different statins have after heart transplantation (HT).
Method: We hypothesize that higher statin intensity is associated with a smaller degree of allograft intimal thickening on intravascular ultrasound (IVUS) at 1-year post-HT. Allograft intima-media thickness (IMT) on the first annual IVUS was retrospectively compared in patients initiated on a low-intensity statin (pravastatin 20 mg daily) versus moderate-intensity statin (atorvastatin 20 mg daily) post-HT.
Curr Opin Organ Transplant
December 2024
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Purpose Of Review: Allograft vasculopathy in vascularized composite allografts (VCA) remains understudied. This review explores the vascular changes in VCA, focused on recent literature.
Recent Findings: Allograft vasculopathy in VCA generally includes progressive concentric myointimal thickening and luminal narrowing of arterial vessels through endothelial deterioration and proliferation of smooth muscle cells.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!